The immunomodulators market had a size of USD 125.4 Billion in 2022 and is projected to reach USD 235.6 Billion by 2032, with a rapid revenue compound annual growth rate (CAGR) of 7.5% during the forecast period. The growth in market revenue is primarily driven by the increasing prevalence of autoimmune diseases, the demand for biologics, and the growing public awareness of the benefits of...